Article
Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2020
Kobayashi Keigo, Soejima Kenzo, Fukunaga Koichi, Shintani Yasushi, Sekine Ikuo, Shukuya Takehito, Takayama Koichi, Inoue Akira, Okamoto Isamu, Kiura Katsuyuki, Takahashi Kazuhisa, Yamamoto Nobuyuki, Takiguchi Yuichi, Miyaoka Etsuo, Okumura Meinoshin, Yoshino Ichiro
Abstract excerpt
INTRODUCTION: The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for EGFR-mutated non-adenocarcinoma (ADC) non-small cell lung cancer patients is not well established. Herein, we investigated key prognostic factors influencing the efficacy of EGFR-TKIs in these patients. METHODS: A total of 12,320 lung cancer patients pathologically diagnosed in 2012 at teaching hospitals in...
Topics
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Humans
- Japan
- Lung Neoplasms
- Mutation
- Prognosis
- Protein Kinase Inhibitors
- Registries
- Retrospective Studies